Literature DB >> 31355862

CAR T-Cell Therapy: A Microcosm for the Challenges Ahead in Medicare.

Caron Jacobson1,2, Amy Emmert2, Meredith B Rosenthal3.   

Abstract

Year:  2019        PMID： 31355862     DOI： 10.1001/jama.2019.10194

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.

Authors:  Kao-Ping Chua; Lauren E Kimmel; Rena M Conti
Journal:  Health Aff (Millwood)       Date:  2021-03       Impact factor: 6.301

2.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

3.  Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.

Authors:  Jonathan E Brammer; Zachary Braunstein; Aashish Katapadi; Kyle Porter; Michael Biersmith; Avirup Guha; Sumithira Vasu; Vedat O Yildiz; Sakima A Smith; Benjamin Buck; Devin Haddad; Richard Gumina; Basem M William; Sam Penza; Ayman Saad; Nathan Denlinger; Ajay Vallakati; Ragavendra Baliga; Raymond Benza; Philip Binkley; Lai Wei; Mason Mocarski; Steven M Devine; Samantha Jaglowski; Daniel Addison
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 12.469

Review 4.  Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

Authors:  Vishwanath Sathyanarayanan; Christopher R Flowers; Swaminathan P Iyer
Journal:  JCO Glob Oncol       Date:  2020-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.